HK1221424A1 - 治療癌症的藥物組合 - Google Patents
治療癌症的藥物組合Info
- Publication number
- HK1221424A1 HK1221424A1 HK16109729.1A HK16109729A HK1221424A1 HK 1221424 A1 HK1221424 A1 HK 1221424A1 HK 16109729 A HK16109729 A HK 16109729A HK 1221424 A1 HK1221424 A1 HK 1221424A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treat cancer
- drug combinations
- drug
- combinations
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361808516P | 2013-04-04 | 2013-04-04 | |
PCT/US2014/033008 WO2014165779A1 (en) | 2013-04-04 | 2014-04-04 | Drug combinations to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1221424A1 true HK1221424A1 (zh) | 2017-06-02 |
Family
ID=50732309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16109729.1A HK1221424A1 (zh) | 2013-04-04 | 2016-08-15 | 治療癌症的藥物組合 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160082019A1 (zh) |
EP (1) | EP2983639A1 (zh) |
JP (1) | JP2016515628A (zh) |
KR (1) | KR20150138268A (zh) |
CN (1) | CN108472242A (zh) |
AU (1) | AU2014248001A1 (zh) |
BR (1) | BR112015025408A8 (zh) |
CA (1) | CA2908815A1 (zh) |
HK (1) | HK1221424A1 (zh) |
MX (1) | MX2015014046A (zh) |
WO (1) | WO2014165779A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2012044572A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
MX366003B (es) | 2013-03-15 | 2019-06-24 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida. |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
MX2021001583A (es) | 2014-02-14 | 2023-02-08 | Exelixis Inc | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. |
US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
CN106715397B (zh) | 2014-07-31 | 2021-07-23 | 埃克塞里艾克西斯公司 | 制备氟-18标记的卡博替尼及其类似物的方法 |
EP3177311A1 (en) | 2014-08-05 | 2017-06-14 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
WO2018136796A1 (en) * | 2017-01-20 | 2018-07-26 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
WO2019143908A1 (en) * | 2018-01-19 | 2019-07-25 | Indiana University Research And Technology Corporation | Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphorylation in cancer |
CR20230287A (es) | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2392564T3 (da) * | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
WO2006014325A2 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
CN104306977A (zh) * | 2006-08-25 | 2015-01-28 | 库伽尔生物科技公司 | 治疗癌症的方法和组合物 |
WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
SG173014A1 (en) * | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
CA2768370A1 (en) * | 2009-07-17 | 2011-01-20 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2012044572A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
CN103664778B (zh) * | 2013-11-27 | 2017-04-05 | 苏州摩尔医药有限公司 | 一种抗肿瘤治疗药物卡博替尼的合成方法 |
-
2014
- 2014-04-04 KR KR1020157030445A patent/KR20150138268A/ko not_active Application Discontinuation
- 2014-04-04 CN CN201480029297.2A patent/CN108472242A/zh active Pending
- 2014-04-04 CA CA2908815A patent/CA2908815A1/en not_active Abandoned
- 2014-04-04 US US14/782,493 patent/US20160082019A1/en not_active Abandoned
- 2014-04-04 EP EP14724594.8A patent/EP2983639A1/en not_active Withdrawn
- 2014-04-04 AU AU2014248001A patent/AU2014248001A1/en not_active Abandoned
- 2014-04-04 JP JP2016506653A patent/JP2016515628A/ja active Pending
- 2014-04-04 BR BR112015025408A patent/BR112015025408A8/pt not_active IP Right Cessation
- 2014-04-04 MX MX2015014046A patent/MX2015014046A/es unknown
- 2014-04-04 WO PCT/US2014/033008 patent/WO2014165779A1/en active Application Filing
-
2016
- 2016-08-15 HK HK16109729.1A patent/HK1221424A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MX2015014046A (es) | 2016-05-16 |
EP2983639A1 (en) | 2016-02-17 |
BR112015025408A2 (pt) | 2017-07-18 |
BR112015025408A8 (pt) | 2018-07-10 |
JP2016515628A (ja) | 2016-05-30 |
AU2014248001A1 (en) | 2015-11-19 |
CA2908815A1 (en) | 2014-10-09 |
US20160082019A1 (en) | 2016-03-24 |
WO2014165779A1 (en) | 2014-10-09 |
KR20150138268A (ko) | 2015-12-09 |
CN108472242A (zh) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221424A1 (zh) | 治療癌症的藥物組合 | |
GB201322725D0 (en) | Cancer therapy | |
HK1211982A1 (zh) | 癌症治療 | |
HK1220900A1 (zh) | 癌症的治療 | |
SG10201801965RA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
SG11201507847UA (en) | Cancer therapy | |
HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
GB201308440D0 (en) | Therapeutic | |
GB201310755D0 (en) | Therapy | |
HK1210023A1 (zh) | 癌症治療 | |
EP2961412A4 (en) | CANCER THERAPY | |
GB201607581D0 (en) | Treatment of cancer | |
GB201318668D0 (en) | Sonosensitive therapeutic | |
HK1232118A1 (zh) | 癌症的治療 | |
GB201518731D0 (en) | Tumour Therapy | |
PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
GB201222563D0 (en) | Cancer treatment | |
GB201317213D0 (en) | Cancer Therapy | |
GB201322347D0 (en) | Treatment of cancer | |
GB201300546D0 (en) | Cancer Treatment | |
GB201318742D0 (en) | Treatment of cancer | |
GB201308529D0 (en) | Treatment of cancer | |
GB201322346D0 (en) | Combination treatment of cancer | |
GB201305020D0 (en) | Treatment of cancer |